Stockpolly
Search
Delisting risk
CRIS · NASDAQ · Biotechnology

Curis (CRIS)

Develops emavusertib combinations for primary central nervous system lymphoma and chronic lymphocytic leukemia.

$1.40
Pre-market+0.01 (+0.43%)
At close$1.39(−2.11%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue332333233100
Cost of revenue000000000000
Gross profit332333233100
15151515131213111091210
Research & development10101010109976667
555543444353
General & administrative555543444353
Operating income−12−12−12−13−11−9−10−8−7−8−12−10
00110−100−127−131
Interest income111100000000
Interest expense020001000000
Other non-operating income0−3−1−10−2001−28130
Income before tax−12−12−12−12−10−10−11−9−819−24−9
Net income from continuing operations−12−12−12−12−10−10−11−9−819−24−9
Net income−12−12−12−12−10−10−11−9−819−24−9
EPS, basic−$2.13−$40.60−$41.00−$40.60−$34.00−$25.00−$25.00−$13.60−$9.80$24.60−$25.00−$4.02
EPS, diluted−$2.13−$40.60−$41.00−$40.60−$34.00−$25.00−$25.00−$13.60−$9.80$24.60−$25.00−$4.02
Weighted average shares, basic600000011112
Weighted average shares, diluted600000011112
EBITDA−12−9−12−12−10−7−11−9−820−24−10
Depreciation & amortization000000000000
EBIT−12−9−12−12−10−7−11−9−820−24−10